TOKENPOST
1 min read
Add as a preferred source on Google

AstraZeneca Says Experimental Stomach Cancer Drug Doubled Survival

The company identified sonesitatug vedotin as the experimental treatment in a late-stage study.

By John Kim
Published
An unmarked glass vial rests in a clinical research lab tray / TokenPost.ai
An unmarked glass vial rests in a clinical research lab tray / TokenPost.ai

A late-stage study found twice the survival time with AstraZeneca’s experimental stomach cancer drug sonesitatug vedotin, the company said.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…